摘要
为探讨基质金属蛋白酶 (MMP2 、MMP9)在肾癌组织中的表达及其与肿瘤侵袭转移和预后的关系 ,选择 3 6例肾细胞癌及 6例正常肾组织 ,采用免疫组化技术 (SP法 )对MMP2 及MMP9进行检测 ,并结合临床资料进行统计、分析。结果显示 ,MMP2 、MMP9在肾癌中的阳性表达分别为 44 4%和 5 2 8% ,二者均阳性者占 3 3 3 %。MMP2 和MMP9在高级、高期肾癌中表达的阳性率明显高于低级、低期患者 (P <0 0 5 ) ,但与肾癌的细胞类型无关。预后调查分析显示 ,MMP2 和MMP9阳性表达者术后 5年存活率均明显低于阴性表达者 (P <0 0 5 )。研究表明 ,MMP2 和MMP9在肾癌组织中可以高度表达 ,并与肾癌的侵袭和转移有关 ,其检测对临床判断肾癌预后有指导意义。
To study the expression of matrical metalloproteinases 2 and 9 (MMP 2 ,MMP 9 ) in human renal cell carcinoma(hRCC) and its relation to prognosis, 36 specimens of human renal cell carcinoma (hRCC) and 6 normal kidneys served as controls were assessed by immunohistochemistry (SP method). The results showed that the positive expression rates of MMP 2 , MMP 9 in hRCC were 44 4% and 52 8%,respectively. There was a significant difference in expression between various grades and stages of hRCC. The expected survival time was shorter in patients with higher expresson of MMP 2 and MMP 9 . Therefore, MMP 2 and MMP 9 are considered as important factors in invasive metastasis and prognosis of hRCC.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2002年第12期1084-1085,共2页
Medical Journal of Chinese People's Liberation Army
